![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, December 03, 2018 8:29:11 AM
Huge fan of the products itself. I feel bad for Andy to a certain degree, then when I look at this past opportunity, and it simply failed in my opinion because we didn't have proper representation for this opportunity. But after this mishap, no matter what anybody else thinks, Andy should now realize that by not bringing GP to the party, this opportunity never had a chance. FDA has always had a horrible reputation of having BIG PHARMA LIVING IN THEIR POCKET! He needs to to step down immediately.
Is it too late to contact GP and have them review everything that went down. If I were the new management coming in, I would definitely have them review this. Could they possibly revive this denial by having an adult rebuttals for their BS arguement men vs women efficacy.
This product will become SOC with the right team in place, THE PRODUCT WORKS GREAT!
My comments above are simply my opinion and nothing more.
I'm enthusiastic at times however I am NOT a professional trader.
Please contact a financial consultant for investment advice.
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM